Servier Partners with n-Lorem Foundation on Preclinical Antisense Oligonucleotide Research for Rare Neurodevelopmental Disorders

Servier and the n-Lorem Foundation entered a multi-target research collaboration on June 10, 2026, to develop antisense oligonucleotide therapies for rare neurodevelopmental disorders. The agreement was announced from Suresnes, France, and San Diego. Under the deal, n-Lorem research teams will use their ASO technology platform to engineer preclinical candidates.

Servier will then advance those candidates into clinical development. Antisense oligonucleotides are designed to target disease-causing RNA and may enable highly personalized approaches to treating genetic disorders. The partnership aims to extend precision genetic medicine to patients living with rare neurological disorders, many of whom currently have no approved treatment options.

Servier is an independent international pharmaceutical company governed by a foundation. The n-Lorem Foundation is a non-profit organization established to provide experimental medicines to treat nano-rare patients with high unmet needs. The collaboration will increase the number of patients n-Lorem can treat.

It also advances Servier's 2030 ambition of developing innovative treatments for rare neurological diseases, including refractory epilepsy, genetically-driven autism spectrum disorders, leukodystrophies, peripheral neuropathies, movement disorders and neuromuscular diseases.

"We welcome Servier to our growing list of supporters and partners and look forward to contributing to Servier's commitment to patients with rare neurological disorders and to advancing ASO technology. This is truly a win, win for patients with rare diseases," said Stanley T.

Crooke, Founder, Chairman and CEO of n-Lorem. "We are proud to partner with n–Lorem, sharing the same commitment to advancing personalized ASOs and bringing meaningful therapies to people living with rare genetic neurological disorders who have few, if any, treatment options available today," said Nitza Thomasson, Global Head of R&D Neurology at Servier.

"This partnership builds on a shared belief in open, multidisciplinary collaboration grounded in strong science to accelerate research and deliver new therapies for patients.